NobleGen Conducts Joint Research to Optimize Mass Production Process of 'Broad-Spectrum Antiviral Drug'
On the 6th, after the signing ceremony of the "Optimization of Mass Production Process for Universal Virus Therapeutics" between NobleGen and Avanto held at the NobleGen Central Research Institute, the attendees took a commemorative photo. From the left: Sangkyu Lee, CEO of Avanto Performance Materials Korea; Wonhyun Hwang, Head of Avanto AMEA Center; Narayana Rao Rapolu, Executive Vice President of Avanto Bio Pharmaceutical Division; Seungseo Hong, Senior Vice Chairman of NobleGen; Youngjun Kim, Director of NobleGen Central Research Institute. Photo by NobleGen
[Asia Economy Reporter Heo Midam] NobleGen (CEO Kim Taehyun) announced on the 6th that it held a signing ceremony for a joint research agreement with Avantor, a Fortune 500 life sciences solutions provider, to optimize the mass production process of a broad-spectrum antiviral drug.
Founded in 1907 and headquartered in Pennsylvania, USA, Avantor is a global company ranked 484th among Fortune 500 companies by revenue in 2020. The signing ceremony took place at NobleGen Central Research Institute, attended by Narayana Rao Rapolu, Executive Vice President of Avantor’s Biopharmaceutical Division; Lee Sangkyu, CEO of Avantor Performance Materials Korea; Hwang Wonhyun, Head of Avantor AMEA Center; Hong Seungseo, Senior Vice Chairman of NobleGen; and Kim Youngjun, Director of NobleGen Research Institute.
NobleGen is a biotech company specializing in the development of broad-spectrum antiviral drugs. Currently, it is conducting government-funded research on treatments for mosquito-borne infectious diseases such as Zika virus and dengue virus. It is also developing treatments for respiratory infectious viruses like COVID-19 and influenza, as well as for herpes zoster virus. This joint research agreement was made because the broad-spectrum antiviral drug NVG308 (research name 3D8 scFv) developed by NobleGen needs to be mass-produced soon.
NobleGen is currently conducting preclinical trials of NVG308 with BioToxTech, the top preclinical CRO in Korea. Avantor plans to have its global technical support team jointly participate to optimize and scale up the mass production process of NVG308. The protein purification resin supplied by Avantor will be applied in this optimization work.
Kim Taehyun, CEO of NobleGen, expressed, “We expect that through research cooperation with a global company like Avantor, we can accelerate the preclinical and clinical trials for the development of broad-spectrum antiviral drugs.”
Avantor, headquartered in Redner, Pennsylvania, USA, is a global company providing essential products and solutions in life sciences, healthcare, advanced technologies, and applied materials industries, and has continuously collaborated with domestic and international biotech companies to overcome the COVID-19 pandemic.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
